Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Principal Investigator: Thompson, J

Assessment of Sexual Function and Quality of Sex Life in Patients with Prostate Cancer and their Partners

Principal Investigator: Aly, Ahmed A

(HCRN GI19-405) A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Principal Investigator: Iyer, Renuka V

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Principal Investigator: Hillengass, Jens

(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)

Principal Investigator: Levine, Ellis G

(EAY 131-A MATCH): Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Principal Investigator: Levine, Ellis G

(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations or Rare Activating Mutations of EGFR

Principal Investigator: Levine, Ellis G

(EAY 131-V MATCH): Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Principal Investigator: Levine, Ellis G

A Phase I/II Open-label Study of Nimotuzumab in Combination with Nivolumab
in Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck
Cancer

Principal Investigator: Dy, Grace K

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Principal Investigator: Levine, Ellis G

(COG ARST1431) A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk …

Principal Investigator: Twist, Clare J

(COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Principal Investigator: Twist, Clare J

Phase IB/II Study of Enzalutamide with Ribociclib in Patients with Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer that retains RB Expression

Principal Investigator: Chatta, Gurkamal S

(COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Principal Investigator: Twist, Clare J

(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas

Principal Investigator: Chowdhry, Varun K

Lung Bronchoscopy Research Samples & Database

Principal Investigator: Ivanick, Nathaniel M

(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Principal Investigator: McCarthy, Philip L

A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients

Principal Investigator: George, Saby

(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy

Principal Investigator: Rokitka, Denise A

(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Principal Investigator: Levine, Ellis G

(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator: Dy, Grace K

(E4512 )A randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Principal Investigator: Chen, Hongbin

(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Principal Investigator: Twist, Clare J

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Principal Investigator: Levine, Ellis G

(A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI…

Principal Investigator: Levine, Ellis G